Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

NCT04939597 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT04939597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04939597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 10, 2022
Completion date
September 30, 2027
Enrollment
162 (actual)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system carcinoma